Galectin Therapeutics Inc (GALT)

Trade GALT now with
1/25/2018 8:37:34 AM Galectin Receives Patents In China And Japan That Support NASH And Cancer Immunotherapy Clinical Development Programs
12/5/2017 8:23:15 AM Galectin Therapeutics Reports Results From Phase 2b NASH-CX Trial
11/13/2017 8:44:09 AM Galectin Announces Presentation Of Preclinical And Early Clinical Data From Phase 1 Clinical Trial Of GR-MD-02
11/7/2017 8:16:27 AM Galectin Therapeutics Q3 Net Loss Applicable To Common Stockholders $4.7 Mln Or $0.13 Per Share
9/12/2017 8:34:57 AM Galectin Receives Notice Of Chinese Allowance To Grant A Key Patent For Composition Of Matter For GR-MD-02
8/14/2017 8:27:10 AM Galectin Therapeutics Q2 Loss Applicable To Stockholders $4.8 Mln Or $0.14/Shr Vs Loss $5.8 Mln Or $0.20/Shr Last Year
4/25/2017 8:14:44 AM Galectin Therapeutics Gets Notice Of Japanese Decision To Grant Composition Of Matter Patent For GR-MD-02
3/28/2017 8:35:08 AM Galectin Therapeutics FY Loss Applicable To Holders Of $22.4 Mln Or $0.76/Shr Vs Loss $21.1 Mln Or $0.88/Shr Last Year
3/14/2017 8:48:52 AM Galectin: GR-MD-02 Shows Clinically Significant Effect In Patients With Severe And Refractory Atopic Dermatitis
3/6/2017 8:34:31 AM Galectin’s GR-MD-02 Shows Efficacy In Patients With Moderate To Severe Plaque Psoriasis